— Enrollment Nearing Completion in Human Acellular Vessel™ (HAV™) Phase 2/3 Trial in Vascular Trauma and Phase 3 Trial in Arteriovenous (AV) Access in Hemodialysis Patients — Multiple publications and scientific meeting presentations highlighting clinical and preclinical HAV results – — Conference call and live webcast at 8:00 a.m. ET today […]
Author: Ken Dropiewski
BioSig Announces New Advisory Board Member Lorraine Spurge
Westport, CT, March 24, 2023 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the appointment of Lorraine Spurge, entrepreneur and financier, to its Advisory […]
JanOne Welcomes John Bonfiglio — Veteran Biotech Executive, Deal Maker and Strategist — to Top Management Team
Bonfiglio is known for raising capital, building start-ups, and leading successful biotech companies as CEO and COO. LAS VEGAS, March 23, 2023 /PRNewswire/ — JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, announced the hiring of John N. Bonfiglio, PhD, as interim […]
Gerry O’Sullivan, the Latest Member to Join Microbot Medical’s Scientific Advisory Board, to Leverage Extensive Interventional Radiology Experience to Progress the LIBERTY® Robotic System Through Regulatory, Clinical and Commercialization Phases
Widely Published Interventional Radiologist Has Earned Well-Regarded Reputation Working with Prestigious Medical Centers in the U.S. and Europe The addition of Professor O’Sullivan, the Clinical Director of Radiology for the Galway Clinic in Ireland, Expands the Company’s EU Presence. HINGHAM, Mass., March 23, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) continues to receive global […]
Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results
– Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; Closed concurrent $75 million private placement – – Company remains on track to submit IND for SGT 003, a next-generation gene therapy for patients with Duchenne; Anticipated dosing in late […]
Acticor Biotech Publishes Its 2022 Annual Results and Provides an Update on Its Clinical Progress
Key milestones achieved in the two Phase 2/3 studies in stroke with glenzocimab: ACTISAVE study: more than 240 patients enrolled to date GREEN study: enrollment of the first patients Exchanges between the University of Birmingham and the UK regulatory authorities for the LIBERATE study in the treatment of myocardial infarction […]
NEW DATA SHOW REMOTE MONITORING TECHNOLOGY LIKE ABBOTT’S CARDIOMEMS HELPS IMPROVE SURVIVAL IN HEART FAILURE PATIENTS
New data found treatment with remote pressure monitoring can significantly reduce mortality risk in heart failure patients CardioMEMS is a tiny implantable sensor that can remotely flag early warning signs of worsening heart failure ABBOTT PARK, Ill., March 21, 2023 — Abbott today announced new data that found monitoring patients […]
Sequana Medical announces additional patents for DSR® in China and the United States
Ghent, Belgium – 22 March 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces further strengthening of the intellectual property portfolio for its DSR (Direct Sodium Removal) program. A key composition of matter patent was allowed in China and […]
Aortix Pump Therapy Leads to Rapid Decongestion and Improved Kidney Function in Hospitalized Patients with Heart Failure and Worsening Renal Function
Late-breaking data presented at THT shows substantial fluid loss and improvements in kidney and cardiac function at 30 days after Aortix therapy Cardiorenal syndrome (CRS) is a complex condition that impacts up to 40% of patients with acute decompensated heart failure and is growing at a double-digit rate HOUSTON, March 21, […]
Ancora Heart’s AccuCinch System Demonstrates Significant Improvement in Quality of Life, Cardiac Structure and Function in Heart Failure Patients
12 Month Data Presented as Late-Breaking Clinical Science at THT 2023 and Simultaneously Published in the Journal of Cardiac Failure BOSTON–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a completely transcatheter device-based therapy to address heart failure (HF), today announced that patients treated with the investigational AccuCinch® Ventricular Restoration System demonstrated improvement […]
Recent
MicroTransponder Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation
New Minimally Invasive Therapy at MemorialCare Heart & Vascular Institute Reduces Cardiovascular Mortality by Nearly 30% in Patients with Resistant Hypertension
Zylox-Tonbridge to Acquire Equity Interest in A European Medical Device Company to Accelerate Expansion in the Global MedTech Market
Popular
- No commented posts yet